SDG 1: Access to antimalarials is key to eliminating malaria, a major cause of poverty

Access to affordable and effective antimalarials is key to eliminating malaria, a major cause of poverty. 

Here are recent key milestones in this area: 

  • 450 million Coartem® Dispersible (artemether-lumefantrine) paediatric treatments distributed in over 50 countries since 2009, saving more than 960,000 children’s lives 
  • 2.8 million Pyramax® (pyronaridine-artesunate) treatments delivered to date, with registration in 29 countries – of which about half were the paediatric Granules formulation
  • 8.6 million Eurartesim® (dihydroartemisinin-piperaquine) treatments distributed between 2011 and 2021
  • 7.6 million artesunate rectal capsules distributed since 2018, saving more than 780,000 lives 
  • 255 million vials of injectable artesunate delivered since 2010, saving an estimated 1.66 million additional lives compared to treatment with injectable quinine
  • Kozenis/Krintafel (tafenoquine) received regulatory approval in Peru for prevention of P. vivax relapse 
  • 540 million ASAQ Winthrop® treatments delivered to date, with registration in 33 countries 
  • TRuST feasibility study, representing first real-world application of tafenoquine, began in September 2021 with interim results received in December 
  • Ganaplacide–lumefantrine yielded positive results in a Phase IIb trial, supporting the continued development of the combination for uncomplicated malaria 
  • 728 million courses of sulphadoxine-pyrimethamine and amodiaquine (SPAQ) have been delivered since the launch of seasonal malaria chemoprevention (SMC) in 2014. In 2021 alone, over 44 million children were protected from seasonal malaria in 13 countries.
  • The Partnership for Vivax Elimination (PAVE) was launched in 2021 with PATH, Menzies School of Health Research and the Burnet Institute to accelerate elimination of relapsing P. vivax malaria